Virostatics
Private Company
Funding information not available
Overview
ViroStatics is a dual-focus biotechnology company with a core R&D pipeline targeting oncology and virology through selective kinase inhibitors, led by its clinical candidate Myrtleciclib. The company supplements its R&D efforts with a specialized contract testing service for respiratory viruses, operating from a BSL-3 facility. Founded and led by experienced biotech entrepreneur Dr. Franco Lori, the company is privately held, has secured EU and Italian research grants, and appears to be in a preclinical/early clinical stage, seeking partnerships for its drug assets.
Technology Platform
Discovery and development of novel, selective host cell kinase inhibitors, with a focus on CDK9/6/4 inhibition via a unique Myc-blocking mechanism. Also operates a BSL-3 bioaerosol testing platform for respiratory viruses.
Opportunities
Risk Factors
Competitive Landscape
In oncology, ViroStatics faces intense competition from approved CDK4/6 inhibitors and a pipeline of next-generation CDK inhibitors from larger, well-funded biopharma companies. Differentiation will rely on demonstrating superior efficacy in hard-to-treat cancers. In virology testing, it competes with other CROs and academic core facilities, where its BSL-3 bioaerosol specialization is a niche advantage.